多發性骨髓瘤市場：KOL 洞察

隨著治療方案的顯著進步，多發性骨髓瘤（MM）領域迅速發展。

本報告檢視了全球多發性骨髓瘤市場，並提供了市場概況以及主要 KOL 的見解，強調將 Darzalex 納入新診斷患者的四合療法中，最近批准 Abecma 和 Carvykti 用於早期治療系列，Tecvayli 和 Elrexfio 等 BCMA 靶向雙特異性抗體的潛力，以及 Talvey 對於接受 BCMA 標靶治療復發的患者的新角色。探索不斷發展的 MM 治療演算法及其對臨床實踐和藥物開發的影響。

目錄

執行摘要

目前與未來的治療演算法

研究目的

單株抗體（mAb）

• 核准的藥物
  • Darzalex (daratumumab; J&J)
  • Sarclisa (isatuximab; Sanofi)

免疫調節藥物（IMiD）

• 研究藥物
  • Iberdomide (CC-220; BMS) and mezigdomide (CC-92480; BMS)

Bcl-2 抑制劑

• 研究藥物
  • Venetoclax (Venclexta/Venclyxto; AbbVie/Roche)

CAR T 細胞療法

• 核准的治療方法
  • Abecma (idecabtagene vicleucel; BMS/2seventy bio) and Carvykti (ciltacabtagene autoleucel; J&J/Legend)
• 管道療法
  • Anitocabtagene autoleucel (CART-ddBCMA; Gilead/Arcellx); zevorcabtagene autoleucel (CARsgen); durcabtagene autoleucel (PHE885; Novartis); BMS-986393 (CC-95266; BMS)

雙特異性抗體

• 核准的藥物
  • BCMA-targeting: Tecvayli (teclistamab; J&J) and Elrexfio (elranatamab; Pfizer)
  • GPRC5D-targeting: Talvey (talquetamab; J&J)
• 研究藥物
  • BMCA-targeting: linvoseltamab (REGN5458; Regeneron); ABBV-383 (AbbVie); alnuctamab (BMS)
  • FcRH5-targeting: cevostamab (Roche)

抗體藥物偶聯物（ADC）

• 研究藥物
  • Blenrep (belantamab mafodotin; GSK)

未來治療趨勢

• 主要見解摘要

附錄

KOL報表

The Multiple Myeloma (MM) landscape is rapidly evolving with significant advancements in therapeutic options. Insights from leading KOLs provide a comprehensive review of the current and future treatment landscape for MM, highlighting the consolidation of Darzalex in quadruplet regimens for newly diagnosed patients, the recent approval of Abecma and Carvykti for earlier treatment lines, the potential of BCMA-targeting bispecific antibodies like Tecvayli and Elrexfio, and the emerging role of Talvey for patients relapsing on BCMA-targeting therapies. Explore the evolving MM treatment algorithm and the implications for clinical practice and drug development.

Table of Contents

Executive summary (1)

Current and future treatment algorithm

Research objectives

Monoclonal antibodies (mAbs) (32)

• Approved drugs (32)
  • Darzalex (daratumumab; J&J) (14)
  • Sarclisa (isatuximab; Sanofi) (18)

Immunomodulatory drugs (IMiDs) (8)

• Pipeline drugs (8)
  • Iberdomide (CC-220; BMS) and mezigdomide (CC-92480; BMS) (8)

Bcl-2 inhibitors (14)

• Pipeline drugs (14)
  • Venetoclax (Venclexta/Venclyxto; AbbVie/Roche) (14)

CAR T-cell therapies (36)

• Approved therapies (26)
  • Abecma (idecabtagene vicleucel; BMS/2seventy bio) and Carvykti (ciltacabtagene autoleucel; J&J/Legend) (26)
• Pipeline therapies (10)
  • Anitocabtagene autoleucel (CART-ddBCMA; Gilead/Arcellx); zevorcabtagene autoleucel (CARsgen); durcabtagene autoleucel (PHE885; Novartis); BMS-986393 (CC-95266; BMS) (10)

Bispecific antibodies (64)

• Approved drugs (42)
  • BCMA-targeting: Tecvayli (teclistamab; J&J) and Elrexfio (elranatamab; Pfizer) (27)
  • GPRC5D-targeting: Talvey (talquetamab; J&J) (15)
• Pipeline drugs (22)
  • BMCA-targeting: linvoseltamab (REGN5458; Regeneron); ABBV-383 (AbbVie); alnuctamab (BMS) (13)
  • FcRH5-targeting: cevostamab (Roche) (9)

Antibody-drug conjugates (ADCs) (13)

• Pipeline drugs (13)
  • Blenrep (belantamab mafodotin; GSK) (13)

Future treatment trends (10)

• Key insights summary (10)

Appendix (4)

• KOL details (4)
  • KOLs from the USA (3)
  • KOLs from Europe (1)

KOL Bulletins (1)